Investing.com - Aslan Pharma ADR reported on Friday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of $-0.02 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.11 on revenue of $0.00.
Aslan Pharma ADR shares are up 3.62% from the beginning of the year and are trading at $2.990 , down-from-52-week-high.They are under-performing the S&P/TSX which is up 17.2% from the start of the year.
Aslan Pharma ADR shares gained 1.36% in intra-day trade the report.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar